Previous 10 | Next 10 |
Health Catalyst ( NASDAQ: HCAT ) announced three new leadership appointments in support of its strategic focus. It includes the appointment of the company's current Chief Revenue Officer, Kevin Freeman, as Chief Growth Officer, and current Chief Brand and Communications O...
Health Catalyst Welcomes Chief Medical Officer Dr. Melissa Welch and Chief Population Health Officer and Senior Vice President Dr. Edward Sheen to Leadership Team PR Newswire SALT LAKE CITY , Aug. 8, 2022 /PRNewswire/ -- Health Catalyst, Inc. ("Healt...
Health Catalyst, Inc. (HCAT) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Adam Brown – Senior Vice President-Finance and Investor Relations Dan Burton – Chief Executive Officer Bryan Hunt – Chief Financial O...
Image source: The Motley Fool. Health Catalyst Inc (NASDAQ: HCAT) Q2 2022 Earnings Call Aug 04, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Health Catalyst Inc (HCAT) Q2 2022 Earnings Call Transcript
Gainers: Cooper-Standard Holdings ( CPS ) +78% . Highway Holdings ( HIHO ) +62% . Pineapple Energy ( PEGY ) +53% . Intelligent Living ( ILAG ) +55% . Progyny ( PGNY ) +41% . Global Blood Therapeutics ( GBT ) +38% . ...
Gainers: Allied Healthcare Products ( AHPI ) +30% . Progyny ( PGNY ) +28% . Kazia Therapeutics ( KZIA ) +21% . Selecta Biosciences ( SELB ) +18% . Sensus Healthcare ( SRTS ) +17% . Losers: Quoin Pharmaceuticals ( QNRX...
Shares of small-cap pharmaceutical data company Health Catalyst ( NASDAQ: HCAT ) plunged 25% to $13.70 in Friday premarket trading, as its weaker-than-expected updated guidance overshadowed its Q2 results beat and a new $40M share buyback program . South Jordan, Utah...
Health Catalyst press release ( NASDAQ: HCAT ): Q2 Non-GAAP EPS of -$0.03 beats by $0.07 . Revenue of $70.63M (+18.5% Y/Y) beats by $0.75M . Financial Outlook Health Catalyst provides forward-looking guidance on total revenue, a GAAP measure, and Adjusted E...
Health Catalyst ( NASDAQ: HCAT ) has announced a stock repurchase program to buyback up to $40M of its common stock. The company plans to fund repurchases with existing cash and cash equivalents, working capital, cash flow from operations or funds available through various...
SALT LAKE CITY, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that its board of directors approved a share repurchase program with autho...
News, Short Squeeze, Breakout and More Instantly...
Health Catalyst Announces New Credit Facility for up to $225,000,000 PR Newswire SALT LAKE CITY , July 18, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst" or the "Company") (Nasdaq: HCAT), a leading provider of data and analytics technology and...
2024-07-01 07:30:03 ET Wells Fargo analyst issues OVERWEIGHT recommendation for HCAT on July 1, 2024 06:12AM ET. The previous analyst recommendation was Overweight. HCAT was trading at $6.39 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...